Previous Article | Next Article 
Journal of Clinical Microbiology, April 2000, p. 1645-1647, Vol. 38, No. 4
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Comparison of a Commercial Enzyme-Linked
Immunosorbent Assay with Immunofluorescence and Complement Fixation
Tests for Detection of Coxiella burnetii (Q Fever)
Immunoglobulin M
Peter R.
Field,1
Jody L.
Mitchell,2
Avelina
Santiago,1
David J.
Dickeson,1
Sau-Wan
Chan,1
David W. T.
Ho,1
Alan M.
Murphy,3
Andrea J.
Cuzzubbo,2 and
Peter
L.
Devine2,*
Centre for Infectious Diseases and
Microbiology Laboratory Services, Institute of Clinical Pathology
and Medical Research, Westmead,1
PanBio, Brisbane,2 and Viral
Diagnostic and Referral Laboratory, North
Ryde,3 Australia
Received 6 August 1999/Returned for modification 17 October
1999/Accepted 3 January 2000
 |
ABSTRACT |
A commercially available enzyme-linked immunosorbent assay (ELISA)
for the diagnosis of Q fever (PanBio Coxiella burnetii immunoglobulin M [IgM] ELISA, QFM-200) was compared to the indirect fluorescent antibody test (IFAT) for C. burnetii IgM and
the complement fixation test (CFT). The ELISA demonstrated 92%
agreement with the reference method (IFAT), and gave a sensitivity of
99% (69 of 70 samples) and a specificity of 88% (106 of 121).
Specificity can be increased with confirmation by IFAT. CFT was found
to have a specificity of 90% (107 of 119), although it was lacking in sensitivity (73%; 51 of 70). No cross-reactivity was observed in the
ELISA with serum samples from patients with mycoplasma (n = 6), chlamydia (n = 5), or
legionella (n = 4) infections, although 2 of 5 patients with leptospirosis and 1 of 4 samples containing rheumatoid
factor (RF) demonstrated positive results in the ELISA. Results
indicate that the performance of the PanBio C. burnetii (Q
fever) IgM ELISA (F = 187) is superior to that of CFT
(F = 163), and consequently the ELISA should be a
useful aid in the diagnosis of acute Q fever.
 |
TEXT |
Coxiella burnetii is the
causative agent of Q fever, a worldwide zoonosis. Infection in humans
results from the inhalation of contaminated aerosols. Although the
clinical signs of acute infection vary, typical symptoms include
fever, headache, myalgia, muscle cramps, hepatitis, and respiratory
complications (8). Chronic manifestations may
include endocarditis and granulomatous hepatitis (8).
Diagnosis of acute Q fever relies mainly on the detection of specific
antibodies to C. burnetii, as culture of the organism is
extremely hazardous (3). Commonly used serological methods include the complement fixation test (CFT), the indirect
immunofluorescent antibody test (IFAT), and the enzyme-linked
immunosorbent assay (ELISA).
IFAT and CFT, although frequently used, have a number of disadvantages.
Both tests are subjective, are not standardized between laboratories,
are inconvenient for large-scale screening, and cannot be automated.
Furthermore, paired sera are usually required when CFT is to be used
for the diagnosis of acute infection, as complement fixation (CF)
antibodies are often not present early in infection but can persist for
long periods after illness (4, 16).
These limitations led to the development of ELISAs that detect
antibodies to C. burnetii (1, 7, 17), including a
commercial ELISA (PanBio, Brisbane, Australia) for the detection
of immunoglobulin M (IgM) antibodies (2). A study of
this IgM ELISA was criticized, as the ELISA was not compared to IFAT
but to CFT only (D. Raoult, Letter, J. Clin. Microbiol.
36:3446, 1998). In this study, we have compared the
performance of the PanBio C. burnetii (Q fever) IgM ELISA to
the reference method (IFAT) and CFT with sera from patients with acute
Q-fever or other infections.
A total of 191 serum samples were included in the study. Of these, 167 were from patients with clinically suspected Q fever that were
submitted to the Centre for Infectious Diseases and Microbiology
Laboratory Services at the Institute of Clinical Pathology and Medical
Research, Westmead, Australia. These specimens consisted of 22 paired
and 43 single serum samples from patients diagnosed with Q fever as
determined by the IgM IFAT result. Of the paired sera, five acute-phase
(S1) sera and all second (S2) sera were positive by IgM IFAT. The
remaining 80 single serum samples were from patients determined not to
have Q fever, based on negative IgM IFAT results. A further 24 sera
with rheumatoid factor (RF) or from patients with infections other than
Q fever were also tested. These comprised 4 single sera falsely
positive for IgM IFAT prior to IgG-RF depletion and 20 single IgM
IFAT-negative sera from patients with serologically confirmed
Mycoplasma pneumoniae (n = 6), Chlamydia
psittaci (n = 5), Leptospira sp. (n = 5), and Legionella pneumophila (n = 4)
infections. These sera were tested with the PanBio C. burnetii (Q fever) IgM ELISA and the CFT.
The PanBio C. burnetii (Q fever) IgM ELISA was performed
according to the manufacturer's instructions. Sera were diluted 1/100 in the diluent provided, which contained goat anti-human IgG to remove
competing IgG and RF. The diluted sera were then transferred to the
purified phase II C. burnetii whole-cell antigen-coated microwells and incubated for 20 min at 37°C (100 µl/well). After washing with phosphate-buffered saline (PBS) containing 0.05% Tween
20, bound IgM (if present) reacted during a 20-min, 37°C incubation
with anti-human IgM peroxidase conjugate (100 µl/well). The plate was
then washed and a 10-min incubation with tetramethylbenzidine substrate
(100 µl/well) was performed. The reaction was stopped by the addition
of 100 µl of 1 M phosphoric acid to each well, and the strips were
read with a microtiter plate reader at a wavelength of 450 nm. Results
were determined by comparison with an IgM reference serum provided
(cut-off calibrator). The initial calibrator value in the IgM ELISA was
increased by 50% to obtain optimal specificity and sensitivity. A
positive sample was defined as having a sample absorbance/calibrator
absorbance ratio (ELISA ratio) of
1.0; a negative sample had a ratio
of <1.0.
IFAT was modified from the methods previously described (7,
12) by the addition of an RF-IgG depletion step using sheep anti-human IgG. Briefly, phase II antigen (Nine Mile strain;
Commonwealth Serum Laboratories, Melbourne, Australia) was diluted,
dropped onto the wells of a glass microscope slide, allowed to dry, and fixed with acetone. After depletion of IgG and RF by treatment with
sheep anti-human IgG (RF absorbent; Dade Behring, Marburg, Germany),
five fourfold dilutions of serum from 1/12 to 1/3,072 in PBS were
reacted with antigen on the slides for 3 h at 37°C and then
washed with PBS. Bound antibody was then detected via a 30-min
incubation with fluorescein-labelled sheep anti-human IgM
F(ab')2 fragment conjugate (Silenus; AMRAD, Melbourne,
Australia). After being washed and dried, slides were mounted with a
coverslip and examined using an incident light fluorescence microscope
(Carl Zeiss, Oberkochen, Germany). Antibody titers were defined as the inverse of the highest dilution with definite staining of C. burnetii membranes. A positive IgM result was defined as having an
end point titer of
48.
CFT was performed as previously described (14). After
determining the optimal dilutions of C. burnetii phase II
antigen, complement, and hemolysin via checkerboard titrations, serial dilutions of serum were prepared in veronal-buffered saline and 2 U
each of antigen and guinea pig complement were added. After an
overnight incubation at 4°C, sensitized sheep cells (2%) were added
and incubated for 1 h at 37°C with intermittent shaking. The
highest dilution with
75% fixation was defined as the end point. A
positive result was defined as having an end point titer of
32.
The individual assay values obtained in the PanBio C. burnetii (Q fever) IgM ELISA showed good correlation with IFAT and
CFT (Fig. 1). There was a significant
correlation between the IFAT or CFT titer and the mean IgM ELISA ratio
(analysis of variance was as follows: for ELISA versus CFT,
F = 43.2 and P < 0.0001; for ELISA
versus IFAT, F = 157.5 and P < 0.0001). Excellent agreement between ELISA and IFAT was obtained
using the modified calibrator, with 92% (175 of 191) serum samples
giving the same result by both methods. The agreement between CFT and
IFAT was 83% (158 of 189). As measured by the sum of sensitivity and
specificity (F value) (9, 22) compared to IFAT,
the overall performance of the ELISA (F = 187) was
significantly better than CFT (F = 163) (Fisher's
exact test, P = 0.0004).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of Q-fever IgM ELISA ratios with IgM IFAT
titers (a) and Q-fever IgM ELISA ratios with CFT titers (b). Mean ELISA
ratios are shown by horizontal bars. The cut-off value (ratio = 1.0) is shown by a broken line.
|
|
As observed in studies with research ELISAs (6, 15), the
ELISA demonstrated a higher sensitivity than CFT (99% versus 73%)
(Table 1), and this difference was
statistically significant (Fisher's exact test, P < 0.0001). The ELISA detected IgM in 5 acute-phase sera before CFT
(Table 2). Similarly, these studies showed that ELISA may be a more sensitive method for Q-fever diagnosis than IFAT (6, 15), and this was observed in this study, in which ELISA detected IgM in one more acute-phase serum than IFAT (Table
2).
The ELISA used in this study showed a slightly lower specificity than
CFT (88 versus 90%), although this difference was not statistically
significant (Fisher's exact test, P = 0.6838 (Table 1). As previously reported (8, 16), the CFT demonstrated good specificity (90%) when IFAT was used as the reference method (Table 1). It is interesting to note that when a cut-off titer of 64 was used, the CFT specificity increased to 95% (113 of 119), while the
sensitivity decreased to 56% (39 of 70). CFT specificity and
sensitivity are related to the level of CF titer selected, and this
work demonstrated the inherent difficulty in selecting a single CF
titer suggestive of recent Q-fever infection (7). Q fever is
difficult to diagnose by CFT with a single convalescent-phase serum
because antibodies can persist, with titers falling at variable rates
(13). Furthermore, CFT is not specific for Q-fever IgM, as
are IgM IFAT and IgM ELISA.
While the CFT did not demonstrate reactivity with sera from patients
with infections other than Q fever, two of the four samples containing
RF gave a positive result. This is probably due to the presence of
either anticomplementary factors or persistent CF antibody from past
infection in the sera. No cross-reactivity was observed in the ELISA
with samples from patients with legionellosis (Table 1), although the
C. burnetii antigen has been reported to express on its
surface epitopes of the common bacterial antigen and eukaryotic
chaperoning protein (5, 11, 19, 20), which has extensive
homology with proteins from other prokaryotes, such as L. pneumophila (10). No cross-reactivity in the ELISA with samples from patients with mycoplasma or chlamydia infection was observed (Table 1). The ELISA did however show elevated levels in sera
from two of five leptospirosis patients and in one of four RF-positive
sera (Table 1), although these results may not be a true representation
of the cross-reactivity in these disease groups due to the low sample
number. It would be interesting to investigate this cross-reactivity
further with a larger number of samples from these groups. In a recent
study of the PanBio Leptospira IgM ELISA (21),
sera from 3 of 34 patients with Q-fever infections were reactive,
though it could not be determined whether this was due to
cross-reactivity or persistent antibody from a previous leptospiral
infection. A previously published study of the PanBio C. burnetii (Q fever) IgM ELISA reported a specificity (20 of 23 samples; 87%) similar to that found in this study, with cross-reactivity observed with sera from patients with M. pneumoniae and Bordetella pertussis infections but not
Epstein-Barr virus or cytomegalovirus infections (2).
Cross-reactivity with M. pneumoniae has been suggested by
Stallman and Allan (18).
The ELISA described in this study provides a standardized method for
Q-fever diagnosis, with a total incubation time of 50 min, suitability
for large-scale screening, and the potential for automation. The
results presented suggest that the PanBio C. burnetii (Q
fever) IgM ELISA is a sensitive and specific alternative for the
diagnosis of Q fever. Samples can be screened in the ELISA, with
positive results confirmed by IFAT if necessary, thus reducing the
number of IFAT tests performed.
 |
ACKNOWLEDGMENTS |
We thank David J. Judd and Eric Kapsalis for technical assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: PanBio Pty.,
Ltd., 116 Lutwyche Rd., Windsor 4030, Queensland, Australia. Phone:
61-7-33571177. Fax: 61-7-33571222. E-mail:
peter_devine{at}panbio.com.au.
 |
REFERENCES |
| 1.
|
Cowley, R.,
F. Fernandez,
W. Freemantle, and D. Rutter.
1992.
Enzyme immunoassay for Q fever: comparison with complement fixation and immunofluorescence tests and dot immunoblotting.
J. Clin. Microbiol.
30:2451-2455[Abstract/Free Full Text].
|
| 2.
|
Devine, P.,
C. Doyle, and G. Lambkin.
1997.
Combined determination of Coxiella burnetii-specific immunoglobulin M (IgM) and IgA improves specificity in the diagnosis of acute Q fever.
Clin. Diagn. Lab. Immunol.
4:384-386[Abstract].
|
| 3.
|
Dupuis, G.,
O. Péter,
R. Luthy,
J. Nicolet,
M. Peacock, and W. Burgdorfer.
1986.
Serological diagnosis of Q fever endocarditis.
Eur. Heart J.
7:1062-1066[Abstract/Free Full Text].
|
| 4.
|
Dupuis, G.,
O. Péter,
M. Peacock,
W. Burgdorfer, and E. Haller.
1985.
Immunoglobulin responses in acute Q fever.
J. Clin. Microbiol.
22:484-487[Abstract/Free Full Text].
|
| 5.
|
Dwyer, D. E.,
V. L. Gibbons,
L. M. Brady, and A. L. Cunningham.
1988.
Serological reaction to Legionella pneumophila group 4 in a patient with Q fever.
J. Infect. Dis.
158:499-500[Medline].
|
| 6.
|
Embil, J.,
J. C. Williams, and T. J. Marrie.
1990.
The immune response in cat-related outbreak of Q fever as measured by the indirect immunofluorescence test and the enzyme-linked immunosorbent assay.
Can. J. Microbiol.
36:292-296[Medline].
|
| 7.
|
Field, P. R.,
J. G. Hunt, and A. M. Murphy.
1983.
Detection and persistence of specific IgM antibody to Coxiella burnetii by enzyme-linked immunosorbent assay: a comparison with immunofluorescence and complement fixation tests.
J. Infect. Dis.
148:477-487[Medline].
|
| 8.
|
Fournier, P. E.,
T. J. Marrie, and D. Raoult.
1998.
Diagnosis of Q fever.
J. Clin. Microbiol.
36:1823-1834[Free Full Text].
|
| 9.
|
Greiner, M.,
D. Sohr, and P. Gobel.
1995.
A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests.
J. Immunol. Methods
185:123-132[CrossRef][Medline].
|
| 10.
|
Hoffman, P. S.,
L. Houston, and C. A. Butler.
1990.
Legionella pneumophila htpAB heat shock operon: nucleotide sequence and expression of the 60-kilodalton antigen in L. pneumophila-infected HeLa cells.
Infect. Immun.
58:3380-3387[Abstract/Free Full Text].
|
| 11.
|
Hoover, T. A., and M. H. Vodkin.
1991.
Cloning and expression of Coxiella burnetii DNA, p. 285-310.
In
J. C. Williams, and H. A. Thompson (ed.), Q fever: the biology of Coxiella burnetii. CRC Press, Boca Raton, Fla.
|
| 12.
|
Hunt, J. G.,
P. R. Field, and A. M. Murphy.
1983.
Immunoglobulin responses to Coxiella burnetii (Q fever): single-serum diagnosis of acute infection, using an immunofluorescence technique.
Infect. Immun.
39:977-981[Abstract/Free Full Text].
|
| 13.
|
Murphy, A. M., and P. R. Field.
1970.
The persistence of complement-fixing antibodies to Q fever (Coxiella burnetii) after infection.
Med. J. Aust.
1:1148-1150[Medline].
|
| 14.
|
Murphy, A. M., and L. Magro.
1980.
IgM globulin response in Q fever (Coxiella burnetii) infections.
Pathology
12:391-396[Medline].
|
| 15.
|
Péter, O.,
G. Dupuis,
D. Bee,
R. Luthy,
J. Nicolet, and W. Burgdorfer.
1988.
Enzyme-linked immunosorbent assay for diagnosis of chronic Q fever.
J. Clin. Microbiol.
26:1978-1982[Abstract/Free Full Text].
|
| 16.
|
Péter, O.,
G. Dupuis,
W. Burgdorfer, and M. Peacock.
1985.
Evaluation of the complement fixation and indirect immunofluorescence tests in the early diagnosis of primary Q fever.
Eur. J. Clin. Microbiol. Infect. Dis.
4:394-396.
|
| 17.
|
Péter, O.,
G. Dupuis,
M. G. Peacock, and W. Burgdorfer.
1987.
Comparison of enzyme-linked immunosorbent assay and complement fixation and indirect fluorescent-antibody tests for detection of Coxiella burnetii antibody.
J. Clin. Microbiol.
25:1063-1067[Abstract/Free Full Text].
|
| 18.
|
Stallman, N. D., and B. C. Allan.
1970.
A survey of antibodies to Mycoplasma pneumoniae in Queensland.
Med. J. Aust.
1:800-802[Medline].
|
| 19.
|
Vodkin, M. H., and J. C. Williams.
1988.
A heat shock operon in Coxiella burnetii produces a major antigen homologous to a protein in both mycobacteria and Escherichia coli.
J. Bacteriol.
170:1227-1234[Abstract/Free Full Text].
|
| 20.
|
Williams, J. C.,
T. A. Hoove,
D. M. Waag,
N. Bhatnagar,
C. R. Bolt, and G. H. Scott.
1990.
Antigenic structure of Coxiella burnetii: a comparison of lipopolysaccharide and protein antigens as vaccines against Q fever.
Ann. N. Y. Acad. Sci.
590:370-380[Medline].
|
| 21.
|
Winslow, W. E.,
D. J. Merry,
M. L. Pirc, and P. L. Devine.
1997.
Evaluation of a commercial enzyme-linked immunosorbent assay for detection of immunoglobulin M antibody in the diagnosis of leptospiral infection.
J. Clin. Microbiol.
35:1938-1942[Abstract].
|
| 22.
|
Xu, H.,
J. Lohr, and M. Greiner.
1997.
The selection of ELISA cut-off points for testing antibody to Newcastle disease by two-graph receiver operating characteristic (TG-ROC) analysis.
J. Immunol. Methods
208:61-64[CrossRef][Medline].
|
Journal of Clinical Microbiology, April 2000, p. 1645-1647, Vol. 38, No. 4
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Setiyono, A., Ogawa, M., Cai, Y., Shiga, S., Kishimoto, T., Kurane, I.
(2005). New Criteria for Immunofluorescence Assay for Q Fever Diagnosis in Japan. J. Clin. Microbiol.
43: 5555-5559
[Abstract]
[Full Text]
-
Thorpe, R., Swanson, S. J
(2005). Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins. CVI
12: 28-39
[Full Text]
-
Field, P. R., Santiago, A., Chan, S.-W., Patel, D. B., Dickeson, D., Mitchell, J. L., Devine, P. L., Murphy, A. M.
(2002). Evaluation of a Novel Commercial Enzyme-Linked Immunosorbent Assay Detecting Coxiella burnetii-Specific Immunoglobulin G for Q Fever Prevaccination Screening and Diagnosis. J. Clin. Microbiol.
40: 3526-3529
[Abstract]
[Full Text]